Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

11.98 -0.51 (-4.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Oric Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...

Via Benzinga

45 Biggest Movers From Yesterday ↗

October 08, 2021

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...

Via Benzinga

ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors ↗

October 07, 2021

ORIC Pharmaceuticals Inc (NASDAQ: ORIC) announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher ↗

October 07, 2021

Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 07, 2021

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of their outstanding shares is at $417.9 million....

Via Benzinga

Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide ↗

October 07, 2021

Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the...

Via Benzinga

Topics Stocks

Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views ↗

October 07, 2021

Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also rose, gaining 1.45% to 4,426.68. The U.S....

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4 ↗

September 21, 2021

The FDA has signed off Oric Pharmaceuticals Inc's (NASDAQ: ORIC) Investigational New Drug Application (IND) for ORIC-533. The Company can now proceed into a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021 ↗

July 06, 2021

Upgrades According to Citigroup, the prior rating for ORIC Pharmaceuticals Inc (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 03, 2021

On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-...

Via Benzinga

The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗

June 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 27, 2021

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 23, 2021

Before 10 a.m. ET Friday, 117 stocks made new 52-week lows. Interesting Points: China Life Insurance Co (NYSE:LFC) was the biggest company in terms of market cap to...

Via Benzinga

The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout ↗

June 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors ↗

June 03, 2021

Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in...

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗

June 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.